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Abstract 
This study aims to determine clinically relevant phenotypic differences between the two most common phenotypic classifications in 
dysferlinopathy, limb girdle muscular dystrophy R2 (LGMDR2) and Miyoshi myopathy (MMD1). LGMDR2 and MMD1 are reported to 
involve different muscles, with LGMDR2 showing predominant limb girdle weakness and MMD1 showing predominant distal lower limb 
weakness. We used heatmaps, regression analysis and principle component analysis of functional and Magnetic Resonance Imaging data 
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to perform a cross-sectional review of the pattern of muscle involvemen  
Outcomes Study for Dysferlinopathy. We demonstrated that there is no cli  
diagnosis. There is a continuum of distal involvement at any given deg  
distally or proximally affected groups. There appeared to be geographi  
common in Japan and LGMDR2 in Europe and the USA. We conclude th  
and therefore should not be split into separate cohorts of LGMDR2 and  
trials or access to subsequent treatments. 
© 2021 The Authors. Published by Elsevier B.V. 
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Dysferlinopathy is an autosomal recessively inherited 
orm of muscular dystrophy, which predominantly affects 
keletal muscle, resulting in progressive weakness and muscle 
asting. 
Several clinical phenotypes are associated with mutations 
n the DYSF gene, most commonly limb girdle muscular 
ystrophy R2 (LGMDR2) and Miyoshi myopathy type 1 
MMD1). LGMDR2 describes a phenotype with predominant 
roximal lower and upper limb weakness at presentation [1] , 
nd was previously called LGMD2B before recent consensus 
eview of LGMD nomenclature [2] . MMD1 describes a 
henotype with predominantly distal lower limb weakness at 
resentation [3] . 
The DYSF gene was identified as the candidate gene 
imultaneously in patients with predominantly proximal 
4] and predominantly distal disease [5] . Patients with the 
ame DYSF mutations, including full siblings, have been 
escribed with clinically different patterns of weakness and 
scribed different phenotypic diagnoses [4–6] . However, 
oubt about the presence of two truly distinct diagnosis was 
aised when pattern of muscle involvement on lower limb 
RI was shown not to differ between LGMDR2 and MMD1 
7] . 
Dysferlinopathy is becoming a focus for clinical trials 
8] . Multiple clinical diagnoses creates difficulties for trial 
esign and therapy licencing. Pharmaceutical companies want 
o develop therapies for as many patients as possible, which 
s particularly important in a rare disease like dysferlinopathy. 
egulators want to know if results from a trial involving 
GMDR2 patients are applicable to patients with MMD1. 
Here we compare the demographic, MRI, functional 
nd genetic differences between 168 genetically confirmed 
ysferlinopathy patients with a clinical diagnosis of LGMDR2 
r MMD1 to determine if they are distinct clinical 
henotypes. 
. Methods 
We analysed data from 168 patients with genetically 
onfirmed dysferlinopathy enrolled in the Jain Foundation’s 266 t in 168 patients from the Jain Foundation’s international Clinical
nically relevant difference in proximal vs distal involvement between
ree of proximal involvement and patients do not fall into discrete
cal preference for a particular diagnosis, with MMD1 being more
at the dysferlinopathies do not form two distinct phenotypic groups
MM for the purposes of clinical management, enrolment in clinical
reativecommons.org/licenses/by-nc-nd/4.0/ ) 
[54] Cohort study; [176] All neuromuscular disease; [185] Muscle disease. 
-year longitudinal Clinical Outcomes Study for 
ysferlinopathy (COS). This study received ethical approval 
n all participating countries. Participants attended 15 
nternational sites for six evaluations (screening, baseline, 
 months, 12 months, 24 months, 36 months) between 
ovember 2012 and March 2018. Visits involved medical 
eview, functional assessments and T1 weighted MRI of the 
ower limb muscles. The study protocol, patient demographics 
nd genetic information, baseline results and a review of 
unctional progression have been previously published [9 , 10] . 
Individual centres identified patients with dysferlinopathy 
rom clinic lists to invite for screening. At study enrolment, 
09 patients were screened and 197 met the inclusion 
riteria. Diagnostic inclusion criteria were the presence of 
) two (predicted) pathogenic mutations in the DYSF gene, 
) one (predicted) pathogenic mutation and absent dysferlin 
n muscle immunoblot or c), one (predicted) pathogenic 
utation and dysferlin protein level ≤20% of normal level 
etermined by blood monocyte testing. Patients also needed 
o be ≥ 10 years of age, able to perform study assessments, 
ttend appointments and provide informed consent. Exclusion 
riteria were the presence of significant co-morbidity (in the 
pinion of the consenting clinician) or anticipated medical 
ntervention which might interfere with ability to attend the 
ssessments. Genetic and protein expression information are 
hown in supplementary Tables 1 and 2 and in Fig. 1 . 
Of these 197, all 10 patients from one site have been 
xcluded from further analysis due to incomplete longitudinal 
ata. One further patient became ineligible, after further 
enetic analysis identified a collagen VI related myopathy. 
Patients’ current clinical diagnosis was reported by the 
ssessing clinician at screening either from reference to 
linical notes (sites seeing local patients) or from patient 
elf-report of the diagnosis given by their usual clinician 
out of area patients). Of the 186 patients, 18 did not 
eport a diagnosis of MMD1 or LGMDR2 – but rather 
roximodistal dysferlinopathy, asymptomatic hyperCKaemia, 
seudometabolic dysferlinopathy or paravertebral muscular 
ystrophy. They were therefore excluded from this analysis, 
eaving 168 patients who had a baseline assessment. Of these, 
ve further patients dropped out before year 2 and three 
issed the visit window, giving 160 (95%) with a 36-month 
ssessment. 
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Fig. 1. Lollipop chart showing the location of pathogenic mutations in dysferlin exons. The chart separates mutations in LGMDR2 patients (top row), MMD1 
patients (second row) and then shows those mutations that occur in both groups of patients (bottom row). The height of the bar corresponds to mutation 
frequency. Black circles denote truncating mutations and green circles denote missense mutations. This figure was generated using the open source ‘mutation 
















































We used Wilcoxon rank sum testing to compare mean age 
f onset of muscle weakness (patient reported) and duration 
f symptoms and Chi-squared testing for comparing gender, 
revious steroid use, teenage exercise level and specific sports 
erformed between groups. 
We categorised teenage exercise levels into high and low, 
ased on the metabolic equivalents and frequency of the 
xercise reported by patients, as previously described [11] . 
igh levels of exercise describe ‘moderate activity multiple 
imes per week or vigorous activity at least weekly’, with low 
evels as less than this. 
To compare the pattern of muscle involvement between 
GMDR2 and MMD1, we used assessments that graded 
unctional ability or pathology in various muscle groups; 
orth Star assessment for limb girdle type muscular 
ystrophies (NSAD), manual muscle testing (MMT) scores 
nd Mercuri scores from T1 MRI. NSAD scores were 
aken from the year 2 study visit. MRI and MMT results 
ere from the baseline assessment as this visit had the 
ost complete assessments. Semiquantitative assessment of 
RIs were performed by a blinded neurologist (RF-T) 
nd radiologist (JL), who independently evaluated axial T1- 
eighted sequences with the Lamminen-Mercuri visual scale, 
s previously reported [12] . Patients with missing data were 
xcluded from the analysis of the scale for which they did not 
ave data. When the scales were combined, only patients with 
ata from all of the scales were included in the comparison. 267 umbers of patients with complete data for each assessment 
re detailed below. 
.1. NSAD score 
The NSAD score is a dysferlinopathy specific functional 
cale of motor performance, developed using RASCH 
nalysis, which demonstrates measurable change over one 
ear in Dysferlinopathy [13] . The scale comprises 29 tasks 
nvolving both upper and lower limbs, testing proximal and 
istal muscle function. Patients can score 0, 1 or 2 in each 
omain of the scale, corresponding to ‘unable to perform 
ask’, ‘modified method, but achieves task independent of 
hysical assistance from another’ and ‘able to perform task’. 
core declines as functional abilities are lost. As the scale was 
eveloped using the first assessments in the natural history 
tudy, direct measurements using the new scale were not 
erformed until the year 2 visit. The NSAD scores used in 
his analysis are therefore from the year 2 visit. 
To compare the order in which functional abilities were 
mpacted, we ordered NSAD items by the cohorts mean score 
or each item. Items with the lowest score were those that 
ewest patients could complete. Thus, the order demonstrated 
he average sequence in which the ability to perform an item 
ere lost. All item scores of each patient with LGMDR2 were 
ompared to those with MMD1 using a heatmap ( Fig. 2 a). 
ean item scores for LGMDR2 and MMD1 patients were 
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Fig. 2. Functional ability on the NSAD score compared by clinical diagnosis. A: Heatmap of individual patients NSAD scores, split by clinical diagnosis of 
LGMDR2 or MMD1 ( n = 130). B: Scatter plot with linear regression line of the mean score on each component of the NSAD assessment for patients with a 



































ompared using linear regression ( Fig. 2 b). Points above 
he regression line represent preserved ability to complete 
hese items, relative to other items, in MMD1 compared 
o LGMDR2. The standardised residual for each item was 
alculated using the R Function “rstandard()”. 
.2. MMT score 
The MMT score is a clinical measurement of strength 
idely used in general clinical practice. We used an 11 point 
onversion of the 5 point MRC scale (0, 1, 2, 3 −, 3, 3 + ,
 −, 4, 4 + , 5 −, and 5) [9] . We ordered each movement by
he mean MMT scores achieved by the cohort, as done for 
SAD scores, and compared scores of each individual patient 
sing a heatmap ( Fig. 3 a). Mean muscle MMT scores for 
GMDR2 and MMD1 patients were compared using linear 
egression ( Fig. 3 b). 
.3. Mercuri score 
Repeating the methods above, a heatmap was created for 
ercuri MRI scores ( Fig. 4 a) and linear regression performed 268 omparing the mean Mercuri score for each muscle between 
he two diagnoses ( Fig. 4 b). Mercuri scoring of the MRIs 
as performed manually with visual inspection of the muscle 
mage [12] . 
.4. Distal to proximal involvement ratio 
To assess for subgroups of distally or proximally affected 
atients irrespective of clinical diagnosis, we compared 
roximal and distal MMT and Mercuri scores. The mean 
MT score of distal muscles was plotted against the mean 
MT score of proximal muscles for each individual to create 
 distal: proximal scatter plot ( Fig. 3 c). This method was 
epeated for Mercuri MRI scores ( Fig. 4 c). All muscle groups 
isted in the heat maps were used. ‘Proximal’ muscles were 
hose above, or working across, the knee or elbow and ‘distal’ 
uscles were below the knee or elbow, working across the 
nkle or wrist. 
As mean values were not normally distributed, the median 
MT ratio was calculated for LGMDR2 and for MMD1 and 
ompared using a Wilcoxon signed rank test. The Spearman’s 
orrelation coefficient between distal and proximal muscle 
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Fig. 3. Pattern of weakness assessed by the MMT score compared by clinical diagnosis. A: Heatmap of individual patients MMT scores, split by clinical 
diagnosis of LGMDR2 or MMD1, ( n = 143). B: Scatter plot with linear regression line of the mean score for each movement tested by MMT for patients 
with a clinical diagnosis of LGMDR2 compared to patients with a clinical diagnosis of MMD1 ( n = 143). C: Scatter plot with linear regression line of mean 


































roups for LGMDR2 and for MMD1 was compared using 
-scores for a two tailed test, after a Fisher z transformation. 
ower calculation demonstrated 87% power to detect a 
ifference in median distal:proximal MMT score ratio of 
 0.2. 
To assess for site specific differences in muscle 
nvolvement, the mean MMT and MRI Mercuri score distal: 
roximal ratios were compared between patients from Tokyo 
high number of MMD1 patients) and Newcastle (high 
umber of LGMDR2 patients) using a scatter plot and 
pearman’s correlation ( Fig. 6 a and b) in the same way as 
or comparing clinical diagnosis. 
Post-hoc power calculations, to assess the ability to 
etect differences between MMD1 and LGMD groups, were 
erformed using an online tool [14] . 
.5. Principle component analysis 
A principal component analysis (PCA) was carried out 
sing the R package ggbiplot [15] . This was completed for 
SAD scores, MMT scores and MRI both individually and 269 ith all three assessments combined. PCA is a statistical 
nalysis and data visualisation tool for comparing multiple 
ariables [16] . It takes all of the variables for each individual 
nd positions that individual on a 2D chart of principal 
omponents, in a way that maximises the variation between 
ndividuals. This means that each variable becomes a vector 
long which individuals are positioned. In this way, groups 
f individuals with distinct characteristics are separated –
or example if MMD1 patients had a weaker soleus muscle 
elative to the rectus femoris than LGMDR2 patients, then 
MD1 and LGMDR2 would form two distinct groups on 
he PCA, without the programmer needing to know which 
ariable would pick out the differences. 
.6. Data availability statement 
Anonymised aggregate data will be provided on reasonable 
equest. Requests should be made to the clinical outcomes 
tudy steering committee by contacting the corresponding 
uthor. 
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Fig. 4. Pattern of weakness assessed by Mercuri scoring of leg T1W MRI compared by clinical diagnosis. A: Heatmap of individual patients Mercuri MRI 
scores, split by clinical diagnosis of LGMDR2 or MMD1 ( n = 59). B: Scatter plot with linear regression line of mean Mercuri score for each leg muscle for 
patients with a clinical diagnosis of LGMDR2 compared to patients with a clinical diagnosis of MMD1 ( n = 59). C: Scatter plot with linear regression line of 





















At baseline, the cohort consisted of 114 patients with a 
linical diagnosis of LGMDR2 and 54 patients with MMD1 
 Table 1 ). Age at symptom onset and at assessment did not 
iffer between clinical diagnoses ( p > 0.05). Median symptom 
uration was higher in MMD1 patients than in LGMDR2 
atients ( p = 0.048). Gender, proportion of non-ambulant 
atients, previous steroid treatment and teenage exercise 
ntensity did not differ between clinical diagnoses ( p > 0.05). 270 .2. Genetics 
LGMDR2 and MMD1 occurred in patients with the 
ame genotype, with 12 patients showing the same pair 
f mutations as a patient with the other clinical diagnosis 
supplementary Table 1 and 2). Discordant phenotypes for 
he same genotype did not segregate based on gender, 
thnicity, location or teenage exercise level. There were 
2 pairs of siblings, who all shared their sibling’s 
iagnosis. 
Patients with both LGMDR2 and MMD1 displayed a range 
f missense, non-sense and splice site mutations throughout 
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Table 1 
Demographic information. 
Clinical diagnosis LGMDR2 MMD1 
Number of participants 114 54 
Median age symptom onset (range) 19 yrs (0–48) 18 yrs (12–46) 
Median age at assessment (range) 36.5 yrs (11–86) 37 yrs (19–62) 
Median symptom duration ∗(range) 14 yrs (1–51) 20 yrs (4–45) 
Male: female 45:69 30:24 
Ambulant 86 (75%) 37(69%) 
Previous steroid treatment 38 (33%) 26 (48%) 
active teenage lifestyle (cat 2/3) 74 (65%) 35 (65%) 
Ethnicity 
White (%) 79 (69%) 38 (70%) 
Asian (%) 21 (18%) 11 (20%) 
Black (%) 3 (3%) 0 (0%) 
Hispanic (%) 9 (8%) 2 (4%) 
Mixed race (%) 2 (2%) 0 (0%) 
Other (%) 0 (0%) 3 (6%) 
Patient location 
Europe (%) 65 (57%) 27 (50%) 
Spain (Barcelona, Seville) 9 (5, 4) 6 (0, 6) 
Italy (Padova) 7 8 
Germany (Berlin, Munich) 11 (4, 7) 2 (0, 2) 
France (Paris) 4 6 
UK (Newcastle) 34 5 
USA (Charlotte, Columbus, Stanford, St Louis, Washington DC) (%) 41 (6, 21, 10, 4, 0) (36%) 17 (6, 2, 2, 2, 5) (31%) 
Australia (Sydney) (%) 4 (4%) 1 (2%) 
Japan ∗∗ (Tokyo) (%) 4 (4%) 9 (17%) 
No difference in age symptom onset or age at assessment on Wilcoxon rank sum test. 
∗ Symptom duration differs between groups ( p = 0.048 on Wilcoxon rank sum test).Gender, previous steroid treatment and teenage activity category not 
significantly different on Chi squared testing. 
















































he length of the DYSF gene. Neither group displayed a 
utational hotspot ( Fig. 1 ). 
.3. NSAD sequence 
NSAD scores were available for 130 patients at visit 5 (86 
GMDR2 and 44 MMD1). Scores were generally lower for 
he MMD1 patients ( Fig. 2 b), suggesting a weaker cohort. 
he sequence in which functional abilities were lost was 
ariable between patients but similar between LGMDR2 and 
MD1 ( Fig. 2 a and 1 b). The most common ability to be lost
as standing on tiptoes for both clinical diagnoses ( Fig. 2 b). 
n general, distal functions appeared below the regression 
ine, suggesting they were more impaired in MMD1 than 
GMDR2 patients for a given overall score, although 
tandardised residuals for all items were small ( < 1.5). 
.4. MMT sequence 
Complete MMT scores were available for 143 patients 
t baseline (visit 2) (95 LGMDR2 and 48 MMD1. Scores 
ere generally lower for the MMD1 patients ( Fig. 3 b). The 
equence in which MMT scores deteriorated was variable 
etween patients ( Fig. 3 a) but similar between LGMDR2 and 
MD1 ( Fig. 3 b). Distal lower limb movements appeared 
lightly more affected in MMD1, (below the regression 
ine in Fig. 3 b), particularly ankle plantar flexion (knee 
exed), which showed the largest residual. Proximal lower 271 imb movements were involved slightly more prominently in 
GMDR2, with hip extension having the largest residual. 
pper limb movements were generally less affected in both 
roups of patients and did not appear to separate by diagnosis. 
verall, while the ratio of mean distal: proximal involvement 
id vary between patients ( Fig. 3 c) it did not vary by 
iagnosis, with no significant difference between median 
istal: proximal ratios (LGMDR2 = 1.06, MMD1 = 0.97, 
 = 0.1) and no difference between regression coefficient 
 p = 0.10) ( Fig. 3 c). Sample size was adequate to detect a
rue difference in ratio of greater than 0.18. These ratios did 
ot highlight discrete groups of distally or proximally affected 
atients, irrespective of diagnosis ( Fig. 3 c). 
.5. MRI sequence 
A complete set of Mercuri scores for thigh and lower leg 
uscles (whole leg) was available for 59 patients (39 LGMD 
nd 20 MMD1) and for lower leg muscles for 131 patients 
84 LGMDR2 and 47 MMD1) at their baseline visit. Mercuri 
cores across all muscles were generally lower for the MMD1 
atients ( Fig. 4 b). Heatmaps and regression showed a variable 
attern of muscle involvement between patients (whole leg –
ig. 4 a, lower leg – Fig. 5 ), but the sequence of severity 
f involvement was similar between LGMDR2 and MMD1 
whole leg - Fig. 4 b). The largest standardised residuals 
ere seen for the gastrocnemius medialis muscle, being more 
rominently involved in LGMDR2 than MMD1, and for the 
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dductor longus muscle, being more prominently involved 
n MMD1 than in LGMDR2. The ratio of mean distal: 
roximal involvement did vary between patients ( Fig. 4 c), but 
ot by diagnosis, with no difference between median distal: 
roximal ratio (LGMDR2 = 1.08, MMD1 = 1.04, p = 0.97) 
nd no difference between regression coefficient ( p = 0.59) 
 Fig. 4 c). Sample size was adequate to detect a true difference 
n ratio of greater than 0.37. These ratios did not highlight 
iscrete groups of distally or proximally affected patients, 
rrespective of diagnosis ( Fig. 4 c). 
.6. Site to site variation 
A greater proportion of Japanese patients had a diagnosis 
f MMD1 (64%) than Europeans (30%, true difference 
n chi-squared p = 0.01) or Americans (32%, p = 0.02). In 
omparing patients from Tokyo (high proportion of MMD1) 
nd Newcastle (high proportion of LGMDR2), there was 
o difference in regression coefficients for distal: proximal 
MT ( p = 0.87) and Mercuri MRI ( p = 0.56) scores ( Fig. 6 a
nd b). In Newcastle, all patients with an MMD1 diagnosis 
howed relative distal weakness on MMT distal: proximal 
atio, while the pattern was more varied in LGMDR2 patients 
 Fig. 6 a). In Tokyo, all patients with an LGMDR2 diagnosis 
howed relative proximal weakness on MMT distal: proximal 
atio, while the pattern was more varied in MMD1 patients 
 Fig. 6 a). On MRI, patients distal: proximal ratio of Mercuri 
cores did not group by diagnosis at either site (Figure b). 
CA analysis of NSAD score, MMT score and MRI did 
ot split Tokyo and Newcastle patients into distinct groups 
 Fig. 7 b) 272 .7. Principal component analysis 
LGMDR2 and MMD1 patients did not separate into 
istinct groups based on PCA analysis of NSAD score, 
MT score or MRI analysis when each scoring systems was 
ssessed individually (data not shown) or when combined 
 Fig. 7 a). 
. Discussion 
We have demonstrated that MMT scores, the NSAD 
nd the pattern of muscle involvement on MRI were 
imilar between the two most common clinical diagnoses in 
ysferlinopathy - MMD1 and LGMDR2. 
Distal involvement was common to both diagnoses, even 
n patients with otherwise mild functional impairment, with 
ifficulty standing on tiptoes being the most commonly 
ffected function in both LGMDR2 and MMD1. Although 
MD1 patients showed a slightly more distal phenotype, with 
nkle plantar flexion (knee flexed) and some distal NSAD 
unctions being more prominently involved than in LGMDR2, 
hese differences were not statistically significant and there 
as a high degree of overlap in pattern of weakness between 
oth diagnoses. Upper limb involvement, as measured by 
MT scores and functional elements, was less common in 
oth diagnosis and distal upper limb weakness was not more 
ommon in either group. 
In addition to the overlap between groups, some patients 
ith an MMD1 diagnosis displayed an LMGDR2 phenotype, 
ith striking preservation of distal strength but marked 
roximal weakness and vice versa for LGMDR2 patients 
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Fig. 6. Comparison of distal vs proximal weakness in Newcastle and Tokyo. A: Mean distal MMT score against mean proximal MMT score for each individual 
patient in Newcastle ( n = 30) and Tokyo ( n = 12). There was no significant difference between Spearman’s R coefficient ( p = 0.87). B: Mean distal Mercuri 
score against mean proximal Mercuri score for each individual patient in Newcastle ( n = 26) and Tokyo ( n = 11). There was no significant difference between 







































isplaying an MMD1 phenotype. This suggests either that 
henotypes were variable and have changed since the time 
f diagnosis, or that factors other than pattern of weakness 
nfluenced the diagnosis. 
One potential factor influencing diagnosis is a sites’ 
revious experience. A clinical diagnosis of MMD1 was 
ore common in Japan while a diagnosis of LGMDR2 was 
ore common in Europe and the United States; however, 
e found no purely ethnic variation in diagnosis prevalence, 
o distinct patterns of weakness on PCA and no variation 
n the degree of distal muscle involvement between sites. 
nly those Tokyo patients with markedly greater proximal 
han distal weakness had an LGMDR2 diagnosis, while 
atients in Newcastle only had an MMD1 diagnosis if they 
ere particularly weak distally. We speculate that this may 
e explained by a geographical preference for diagnosis. 
apanese sites may be more likely to diagnose MMD1 as 
he default, unless presentation is strikingly different, due to 
ite experience, as MMD1 was first described in a Japanese 
ohort [3] . LGMDR2 may be the default diagnosis in the 273 est, having been first described in a European cohort [1] . 
owever, we did not assess what the pattern of weakness 
as at initial presentation. It remains possible that a true 
ifference in pattern of presentation exists, but this study 
as not close enough to the time of diagnosis, and that 
MD1 and LGMDR2 were both described in the geographic 
ocations where each presentation was more common. 
A potential weakness in this study is the wide range 
f age and disease severity of patients when they were 
ssessed. MMD1 patients had generally had symptoms for 
onger, were slightly weaker than the LGMDR2 patients and 
ay have presented later initially if they only had mild 
alf weakness. In addition, because the NSAD assessment 
as developed and validated during COS, the most complete 
cores were from the year 2 (5th) visit, adding a further 2 
ears to each individual’s disease progression at the point of 
ssessment. The variation between individuals was greatest 
n less affected patients, so it is possible that a larger 
ohort of minimally affected patients would demonstrate true 
henotypic differences. However, in this cohort, even amongst 
U. Moore, H. Gordish, J. Diaz-Manera et al. Neuromuscular Disorders 31 (2021) 265–280 
Fig. 7. Principal component analysis of assessments between a. diagnosis and b. study site. A: Principle component analysis (PCA) of NSAD, MMT scores 
and lower leg Mercuri MRI score showing no difference in weighting of principle components between diagnoses. B: Principle component analysis (PCA) of 












































he mildly affected patients, the pattern of muscle involvement 
aried and overlapped between diagnostic groups. Even if 
here were a difference early in the disease course, it seems 
hat the clinical diagnoses given at presentation does not 
ontinue to best describe the phenotype of a dysferlinopathy 
atient several years into their disease. 
Although not forming distinct groups, a wide range 
n pattern of muscle involvement is evident and suggests 
here may be multiple, rather than a single, genetic or 
nvironmental disease modifying factors [17] . The variation 
s not explained by the underlying dysferlin mutations, as 
atients in this (and previous) studies with the same dysferlin 
enotype have different clinical diagnoses and patterns of 
eakness [5 , 6] . Although siblings in this cohort shared the 
ame clinical diagnosis, previous studies have demonstrated 
therwise [6] . Ethnicity also does not seem to influence 
iagnostic prevalence. We also reviewed exercise intensity and 
ype, which are known to vary culturally, [18] but did not 
dentify any association with clinical diagnosis. This suggests 
hat pattern of weakness is not related to demographic factors, 
uch that these findings should be generalizable to the wider 
opulation of patients with dysferlinopathy. 
The patient population with dysferlinopathy demonstrate 
ariation in rates of disease progression and the degree 
f distal:proximal muscle involvement, particularly early in 
he disease. Developing interventional therapies for such a 
eterogenous cohort is complex and there are incentives 
o form smaller, more homogeneous cohorts of patients. 
owever, for several reasons, we argue that a patient’s clinical 274 iagnosis should not be the element used to create cohorts for 
linical trials: 
) Diagnostic criteria for each diagnosis are not clearly 
defined allowing individual and regional variation in 
ascribing diagnosis. 
) There is significant phenotypic overlap between clinical 
diagnostic groups even in early stages. 
) Validated, dysferlinopathy specific, outcome measures (the 
NSAD) are available that incorporate both distal and 
proximal muscle functions to allow progression to be 
monitored across the spectrum of disease. 
) Outcome measures including the NSAD, 10 m walk and 
timed up and go show no difference in rate of progression 
over three years between patients with MMD1 and 
LGMDR2 [19] . 
These points suggest that combining the clinical diagnoses 
f MMD1 or LGMDR2 into a common unified group of 
dysferlinopathies’, is important for clinical trials in order to 
revent potential detrimental artificial distinctions and the risk 
ftreatments being developed with and for one specific group 
nd not the other, when both could benefit. 
Mutations in the DYSF gene are associated with multiple 
ifferent clinical diagnoses, including LGMDR2 and MMD1. 
e have shown that pattern of weakness did not separate 
atients into distinct clinical entities, with significant 
unctional overlap between and within diagnostic groups. 
nitial clinical diagnosis was not a reliable predictor of future 


































































attern of weakness, functional ability or rate of deterioration. 
herefore, for the purposes of monitoring and the evaluation 
f therapeutic interventions, we recommend that patients with 
ysferlinopathy be considered as a single cohort, rather than 
eing separated based on initial clinical diagnosis. 
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